News

SOTIO Presents Poster on CLAUDIO-01 Trial at ESMO Congress

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting a trial-in-progress poster at the European Society for Medical Oncology Congress taking place October 20-24, 2023 in Madrid, Spain. 

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

• SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
• Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
• Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

• Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population.
• Phase 1/2 study is evaluating SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers.

SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer

• CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)
• The trial will enroll up to 109 patients with gastric and pancreatic cancer

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patient in its Phase 1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. SOT102 is the lead program of SOTIO’s growing ADC pipeline built on multiple platforms.

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

• PPF Group provides funding to advance SOTIO through key clinical milestones
• Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
• Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

• SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programs
• Rights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based on certain developments and regulatory achievements, including upfront and near-term success dependent milestones worth up to $29.5 million
• SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. (LCB, KOSDAQ: 141080), a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.

SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies

• Results from preclinical, proof-of-concept studies were presented at the 2021 AACR Annual Meeting
• Results demonstrate strong potential of SOT102 to eliminate tumor cells in a target-specific manner
• First-in-human study in gastric and pancreatic cancer patients with expected launch in early 2022

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, announced new preclinical data of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors in a virtual poster presentation at the 2021 American Association of Cancer Research (AACR) Annual Meeting. The data, which demonstrate that SOT102 has strong potential to eliminate CLDN18.2-expressing tumor cells in a target-specific manner, provide proof of concept for SOT102 as well as SOTIO’s proprietary ADC platform.

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors.

Acquisition agreement with Boehringer Ingelheim for NBE-Therapeutics marks first major biotech exit for PPF Group

• €1.18 billion acquisition provides for significant returns to PPF Group as NBE’s largest shareholder
• SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE

PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020. 

SOTIO and NBE-Therapeutics sign collaboration and license agreement for next-generation antibody-drug conjugates

Basel, Switzerland & Prague, Czech Republic – NBE-Therapeutics AG and SOTIO a.s. today announced that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAb^TM antibody platform, its site-specific SMAC^TM conjugation technology and its novel ultra-potent toxin platform. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products.